BioLife Solutions (NASDAQ:BLFS) Given New $31.00 Price Target at TD Cowen

BioLife Solutions (NASDAQ:BLFS) had its price objective upped by TD Cowen from $28.00 to $31.00 in a research report sent to investors on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the medical equipment provider’s stock.

Several other research firms have also recently weighed in on BLFS. Craig Hallum increased their price target on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday. Northland Securities raised their target price on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. Finally, HC Wainwright started coverage on shares of BioLife Solutions in a research note on Monday, September 30th. They issued a “buy” rating and a $29.00 price objective on the stock. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $27.83.

BioLife Solutions Stock Down 9.0 %

BLFS opened at $24.11 on Wednesday. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -22.75 and a beta of 1.88. The firm has a 50 day moving average price of $24.11 and a 200-day moving average price of $22.73. BioLife Solutions has a twelve month low of $11.00 and a twelve month high of $28.88. The company has a quick ratio of 1.81, a current ratio of 2.86 and a debt-to-equity ratio of 0.04.

Insider Activity

In related news, CRO Garrie Richardson sold 3,070 shares of the stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the completion of the sale, the executive now owns 114,773 shares in the company, valued at approximately $2,883,097.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at approximately $7,593,412.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CRO Garrie Richardson sold 3,070 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $25.12, for a total value of $77,118.40. Following the transaction, the executive now owns 114,773 shares of the company’s stock, valued at $2,883,097.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,044 shares of company stock worth $645,105 over the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On BioLife Solutions

Hedge funds have recently bought and sold shares of the business. 1620 Investment Advisors Inc. purchased a new stake in shares of BioLife Solutions in the second quarter valued at $35,000. Isthmus Partners LLC raised its position in BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after purchasing an additional 42,265 shares during the period. Quest Partners LLC bought a new stake in BioLife Solutions in the third quarter worth about $57,000. GAMMA Investing LLC boosted its position in shares of BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares during the period. Finally, Canada Pension Plan Investment Board bought a new position in shares of BioLife Solutions during the second quarter valued at approximately $122,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.